Business
Amgen And The International Federation of Psoriasis Associations Launch UPLIFT Innovation Challenge
Challenge to Support an Innovative Solution That Addresses Disconnect in Perception of Psoriatic Disease Severity and Undertreatment Documented in
About this update from Amgen Inc.
[{"type":"text","content":"Challenge to Support an Innovative Solution That Addresses Disconnect in Perception of Psoriatic Disease Severity and Undertreatment Documented in Multinational UPLIFT Survey\n UPLIFT Data Presented at WPPAC 2021 Report Substantial Disease Burden for People Living With Psoriasis and Psoriatic Arthritis\n\n\nTHOUSAND OAKS, Calif., July 14, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN), in partnership with the International Federation of Psoriasis Associations (IFPA), announced the launch of the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Innovation Challenge, a new global initiative that aims to make a big impact within the psoriatic disease community by fostering the development of actionable solutions to address a challenge that people living with psoriatic disease and healthcare providers continue to face. Applicants are invited to submit innovative ideas that address the challenge question: \"How can we unite people living with psoriatic disease and their healthcare providers to achieve optimal health outcomes?\" \nAmgen and IFPA created the UPLIFT Innovation Challenge in response to the undertreatment and strong disconnect between patients' perceptions and standard measures of disease severity documented in the 2020 UPLIFT survey. Data from UPLIFT was presented virtually during the 6th World Psoriasis & Psoriatic Arthritis Conference (WPPAC), June 30 - July 3, 2021. \nThe challenge is open to all local, regional and national psoriasis- and psoriatic arthritis-focused patient organizations worldwide. Entrants must submit applications by 23:59 EDT on Monday, August 30, 2021, and rules and additional details are available at www.UPLIFTInnovationChallenge.com. The successful applicant will receive a one-time donation or grant of $25,000 USD (or equivalent in local currency)1 to support the execution of their proposed solution. \n\"Despite tremendous advances in recent years, significant areas of unmet need remain for people living with psoriatic disease,\" said Frida Dunger Johnsson, executive director, IFPA. \"Patient organizations are uniquely positioned to develop and implement solutions that address these needs as we are on the front lines, constantly working to help improve the lives of people with psoriatic disease. We chose to partner with Amgen on the UPLIFT Innovation Challenge as a global oppo...